Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 24 of 245 for:    "ottawa heart institute"

Pilot Study to Evaluate Right Ventricular Function With Riociguat in CTEPH

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02094001
Recruitment Status : Completed
First Posted : March 21, 2014
Last Update Posted : August 29, 2018
Sponsor:
Collaborator:
Bayer
Information provided by (Responsible Party):
Lisa Mielniczuk, Ottawa Heart Institute Research Corporation

Brief Summary:

Chronic thromboembolic Pulmonary hypertension(CTEPH) is characterized by obstruction of the pulmonary vasculature, leading to increased pulmonary vascular resistance, progressive pulmonary hypertension (PH) and right ventricular failure- most common cause of death for patients with PH. Riociguat, (ADEMPAS) is a member of a new class of drug recently approved in Canada for the treatment of CTEPH.

This pilot study is designed to assess if at least 24 weeks of treatment with riociguat will show changes in glucose metabolism and improved resting myocardial blood flow using positron emission tomography ( PET ) imaging to measure myocardial function. The response between both treatment naive patients as well as patients on maximally tolerated dose of riociguat with tratment duration of at least 3 months will be included.


Condition or disease Intervention/treatment Phase
Chronic Thromboembolic Pulmonary Hypertension Radiation: Cardiac PET imaging using F-18-FDG, N-13 ammonia( NH3) Phase 2

Detailed Description:

It remains unclear as to why certain patients with PH develop right heart failure. Several lines of evidence suggests alterations in right ventricular (RV) function may be precipitated by RV ischemia. This ischemia results from both decreased right coronary artery perfusion pressure and from arteriolar- capillary rarefaction. It has been proposed that this contributes to insufficient oxygen delivery needed to support the increase RV demand in right heart failure (RHF), this stimulating glycolytic shift. However, this glycolysis is insufficient to compensate for suppression of glucose oxidation in severe right ventricular hypertrophy (RVH), resulting in a state of RV hibernation and progressive RHF.

This study is designed to assess if 24 weeks of treatment with riociguat will be associated with changes in glucose metabolism and improved RV blood flow using N-13-ammonia (NH3) to measure myocardial perfusion.

We will assess the response in both treatment naive patients as well as patients who have been titrated to maximally tolerated doses of riociguat with total treatment duration of at least 3 months.

The assessment of quantitative myocardial blood flow will be combined with an advanced 3 dimensional echocardiographic assessment of RV volume and function and with cardiac magnetic resonance (MR).


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 6 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Evaluation of Right Ventricular Function and Metabolism Following Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension- Images of Rio
Actual Study Start Date : May 2014
Actual Primary Completion Date : June 2016
Actual Study Completion Date : June 2016


Arm Intervention/treatment
Experimental: Riociguat therapy
After an overnight fast, patients will undergo a 20 minute dynamic PET scan with injection of 3 MBq/kg of N-13 ammonia (NH3) to measure myocardial perfusion. Followed by a 60 min dynamic PET scan with injection of 3MBq/kg of F-18-FDG to measure glucose uptake.
Radiation: Cardiac PET imaging using F-18-FDG, N-13 ammonia( NH3)
After an overnight fast, patients will undergo a 20 minute dynamic PET scan with injection of 3 MBq/kg of N-13 ammonia (NH3) to measure myocardial perfusion. Followed by a 60 min dynamic PET scan with injection of 3MBq/kg of F-18-FDG to measure glucose uptake.




Primary Outcome Measures :
  1. Evidence of changes in glucose metabolism and myocardial RV blood flow in patients treated with riociguat using PET imaging. [ Time Frame: After 24 weeks of treatment with riociguat. ]
    Subjects will undergo FDG (fluorodeoxyglucose, F-18)cardiac positron emission tomography studies (PET) at baseline and 24 weeks to assess regional myocardial blood flow. The assessment of regional myocardial blood flow will be combined with 3D echocardiography and magnetic resonance (MR)


Secondary Outcome Measures :
  1. Evidence of improved RV function and volumes using 3D echocardiography and magnetic resonance imagining (MRI) [ Time Frame: baseline and 24 weeks ]
    The assessment of will be obtained by 3D echocardiography and MRI to evaluate RV function.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients must be able to provide their written informed consent to participate in the study after having received adequate previous information and prior to any study specific procedures.
  • At least 18 years of age at the time of screening.
  • Receiving riociguat therapy for CTEPH.
  • Patients with inoperable CTEPH or persistent or recurrent PH, after undergoing pulmonary endarterectomy.
  • CTEPH diagnosis will be based on either Ventilation/ Perfusion scan (V/Q), pulmonary angiography or computed tomography pulmonary angiography..
  • Clinical right heart catheterization performed confirming mean pulmonary artery pressure (mPAP >25 mmHg).
  • Pulmonary vascular resistance (PVR) > 300 dyne/sec/cm5

Exclusion Criteria:

  • • All types of pulmonary hypertension except Dana Point Classification Group 4 (1).

    • Patients who are currently taking Phosphodiesterase type 5 (PDE-5) inhibitors, ERAs and prostanoids ≤ 3 days prior to start of riociguat treatment.
    • Pulmonary endarterectomy surgery within 3 months of screening.
    • Epicardial coronary artery disease (Ejection Fraction <40%).
    • Previous myocardial infarction within the 3 months prior to screening.
    • Severe proven or suspected coronary artery disease (CCS Angina Classification II-IV), and/or requiring nitrates.
    • Uncontrolled arterial hypertension (systolic blood pressure> 180 mmHg and/or diastolic BP> 110 mmHg.
    • Systolic blood pressure <95mmHg.
    • Resting heart rate in an awake patient <50 beats per minute (bpm) or >105 bpm.
    • History of uncontrolled atrial fibrillation within the last 3 months prior to screening.
    • Hypertrophic obstructive cardiomyopathy.
    • Clinical evidence of symptomatic atherosclerotic disease (peripheral artery disease).
    • Pregnant or breastfeeding women or women with childbearing potential not using highly effective contraception methods.
    • Renal insufficiency (glomerular filtration rate < 30 ml/min.
    • ALT or AST > times upper limit of normal( ULN) and/or severe hepatic insufficiency.
    • Contraindication to MRI imaging.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02094001


Locations
Layout table for location information
Canada, Ontario
University of Ottawa Heart Institute
Ottawa, Ontario, Canada, K1Y4W7
Sponsors and Collaborators
Ottawa Heart Institute Research Corporation
Bayer
Investigators
Layout table for investigator information
Principal Investigator: Lisa M Mielniczuk, MD Ottawa Heart Institute Research Corporation

Layout table for additonal information
Responsible Party: Lisa Mielniczuk, Medical Director, Pulmonary Hypertension Clinic, Ottawa Heart Institute Research Corporation
ClinicalTrials.gov Identifier: NCT02094001     History of Changes
Other Study ID Numbers: 20130903-01H
First Posted: March 21, 2014    Key Record Dates
Last Update Posted: August 29, 2018
Last Verified: June 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertension
Hypertension, Pulmonary
Vascular Diseases
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases
Fluorodeoxyglucose F18
Riociguat
Radiopharmaceuticals
Molecular Mechanisms of Pharmacological Action
Enzyme Activators